Background
==========

Inhaled β~2~-adrenoceptor (β~2~-AR) agonists represent a first-line treatment of bronchial asthma. However, a reduced response to β~2~-AR agonists has been observed in asthmatic subjects and it has been suggested to play a role in airway hyperresponsiveness \[[@B1],[@B2]\]. Although genetic factors may influence responses to β-agonists \[[@B3],[@B4]\], it is believed that the reduced response of β~2~-AR may result from use of β-agonists leading to receptor desensitization \[[@B5],[@B6]\]. Moreover, β~2~-AR desensitization can be induced in human airway smooth muscle cells (HASMC) by exposure to inflammatory mediators that are likely to be present in the asthmatic airways \[[@B7],[@B8]\]. In allergic asthma, several products are released from either resident or circulating inflammatory cells or even from the HASMC themselves \[[@B9]\] upon exposure to allergen. Among these mediators, cysteinyl-leukotrienes (cysteinyl-LTs) are long known to play an important role in asthma \[[@B10],[@B11]\]. Cysteinyl-LTs originate from the oxidative metabolism of arachidonic acid through 5-lipoxygenase in different inflammatory cells and are released upon exposure to sensitizing allergens \[[@B12],[@B13]\]. Cysteinyl-LTs exert a variety of effects with relevance to the etiology of asthma \[[@B14]\], like smooth muscle contraction \[[@B15]-[@B17]\] and proliferation \[[@B18],[@B19]\], eosinophil recruitment into the airways \[[@B20]\], increased microvascular permeability \[[@B21]\], enhanced mucus secretion and decreased mucus transport \[[@B12],[@B22]\]. Furthermore, in passively sensitized human bronchi, the response to β~2~-AR agonists is reduced after allergen exposure, and this can be prevented by either a cell membrane stabilizer or a leukotriene receptor antagonist, suggesting a role for cysteinyl-LTs released by resident inflammatory cells regulating β~2~-AR function \[[@B23]\]. Consistent with this hypothesis is the clinical observation that concurrent administration of salbutamol and the CysLT~1~receptor (CysLT~1~R) antagonist montelukast affords greater protection against exercise- and hyperventilation-induced asthma than salbutamol alone \[[@B24]\].

The intracellular mechanisms through which cysteinyl-LTs may cause β~2~-AR desensitization in asthmatic airways have not been fully investigated. In the present study, we tested the hypothesis that cysteinyl-LTs may cause β~2~-AR desensitization through the activation of protein kinase C (PKC). For this purpose, the isoproterenol-induced cAMP production was first studied in HASMC pre-incubated with exogenous LTD~4~or the PKC activator phorbol-12-myristate-13-acetate (PMA). Then, the effects of montelukast and the specific PKC inhibitor GF109203X were compared in LTD~4~-challenged HASMC. Possible effects of LTD~4~on protein kinase A (PKA) or adenylyl-cyclase were assessed by treatments with the PKA inhibitor H89 or forskolin. The hypothesis that the LTD~4~-PKC pathway may also be involved for allergen-induced β~2~-AR desensitization was tested by assessing the effects of montelukast and GF109203X in passively sensitized human bronchial rings challenged with allergen.

Methods
=======

Materials
---------

Smooth muscle cells from human bronchi were purchased from Invitrogen-Cambrex (Walkersville, MD). Cell culture supplies, forskolin, PMA, isobutylmethylxanthine (IBMX) and isoproterenol were purchased from Sigma Chemical Co (St. Louis, MO); LTD~4~and cAMP EIA kit from Cayman Chemical Co. (Ann Arbor, MI); montelukast was a gift from Merck & Co. (West Point, PA). GF109203X and H89 were from Calbiochem (La Jolla, CA). DC™Protein assay from Bio-Rad Laboratories (Richmond, CA). Bronchial rings for functional studies were obtained from 6 non-asthmatic patients undergoing thoracotomy for lung cancer.

HASMC studies
-------------

Monolayers of HASMC from human bronchi were grown in Minimum Essential Medium supplemented with 10% FBS, 100-U/ml penicillin, and 100-μg/ml streptomycin, as previously described in detail \[[@B25]\]. Cells were used between 3^rd^and 8^th^passage at a 1:3 ratio in 75-cm^2^culture flasks. At least two different cell line have been used.

Accumulation of cAMP was measured in cells grown to confluence in 12-well plates and serum-starved for 24 h. Cells were incubated at 37°C for 10 min in 1-ml PBS containing 3 × l0^-4^M ascorbic acid and 10^-3^M isobutylmethylxanthine. Reactions were stopped by placing the plates on ice, cells were then washed once with cold PBS and 150 μl of l0^-1^M HC1 were added to each well. After 20-min incubation, cells were scraped and centrifuged 12000 × g for 10 min. Supernatant solutions were first assayed for protein concentration and then for cAMP content using a cAMP EIA-kit following manufacturer\'s instructions. cAMP concentrations of unknown samples were determined by computer-assisted interpolation from a standard curve.

Concentration-response curves of cAMP accumulation in response to isoproterenol (10^-9^M to 10^-4^M) were obtained in HASMC at control (vehicle treated) or after exposure to LTD~4~(10^-6^M for 30 min), with or without 30-min pre-incubation with 10^-6^M GF109203X. The increase of cAMP above baseline in response to 10^-5^M isoproterenol was studied in HASMC at control and after 30-min exposure to 10^-6^M LTD~4~or 5 × l0^-7^M PMA, with or without 10^-6^M montelukast, GF109203X, or H89. The effect of 10^-4^M forskolin was studied by 10-min incubation after 30-min exposure to either vehicle or LTD~4~.

Bronchial tissue studies
------------------------

24 bronchial rings from surgical specimens were passively sensitized against dust mites by an overnight incubation (18 h) at room temperature with serum pooled from three atopic subjects diluted 1:9 in aerated (95% O~2~, 5 % CO~2~) PSS of the following composition (mM): NaCl 110.5, KC1 3.4, CaCl~2~2.4, MgSO~4~0.8, KH~2~PO~4~1.2, NaHCO~3~25.7, and dextrose 5.6, as previously described in details \[[@B26]\]. The serum specific concentrations of specific IgE for Dermatophagoides Pteronyssinus and D. Farinae were larger than 13.2 Phadebast RAST units/ml (Pharmacia, Uppsala, Sweden) and the total serum concentration was 180 ± 33 international units/ml. Nineteen sensitized rings were incubated with montelukast (10^-7^M, n = 5 and 10^-6^M, n = 5), or GF109203X (10^-7^M, n = 2 and 10^-6^M, n = 1), or PSS (n = 6) for 30 min and then challenged by a 60-min incubation with 200 AU/ml of Dermatophagoides mix at 37°C. Challenged rings incubated with PSS alone served as control (n = 6). Rings were then suspended in water-jacketed 25-ml tissue baths containing aerated PSS at 37°C using two stirrups connected to a fixed hook at the bottom of the tissue bath and to a force transducer via a silk string, respectively. Rings were gradually stretched until a steady reference length of 1 gr was achieved. PSS was changed every 20 min. All rings were contracted with 10^-6^M carbachol and, after a steady contraction was achieved, relaxed with salbutamol added cumulatively from 10^-9^M to 10^-4^M with half-Log increments. Each concentration-response curve was fitted by sigmoid least-square interpolation between extreme values constrained at 100% (maximal carbachol-induced force) and 0 (minimal force at 10^-4^M salbutamol).

Statistical analysis and experimental design
--------------------------------------------

All curves shown were analyzed by Prism-4 software using the four parameters logistic equation and parameters compared using the extra sum of square principle \[[@B27]\]. Parameter errors are expressed as percentage coefficient of variation (%CV) and calculated by simultaneous analysis of at least two different and independent experiments performed in duplicate or triplicate (for HASMC). One-way independent or two-way repeated-measure analysis of variance (ANOVA) were used whenever appropriate with Dunnett or Bonferroni post-hoc tests for multiple comparisons. P values \< 0.05 were considered statistically significant. Data are expressed as means ± S.E.M.

Results
=======

Isoproterenol-induced cAMP accumulation in HASMC culture
--------------------------------------------------------

Increasing concentrations of isoproterenol caused a concentration-dependent accumulation of cAMP in all experiments.

After challenge with LTD~4~(Fig. [1A](#F1){ref-type="fig"}) the maximum cAMP accumulation was significantly (P \< 0.05) reduced (33%) from 4109 pmol/mg prot (CV 10%) to 2760 pmoles/mg prot (CV 13%), whereas EC~50~was substantially unaffected (from 0.68 μM, CV 59% to 0.69 μM, CV 82%). In montelukast-treated and LTD~4~-challenged HASMC (Fig. [1B](#F1){ref-type="fig"}), isoproterenol-induced cAMP accumulation was not significantly different from unchallenged HASMC and significantly greater than in untreated LTD~4~-challenged HASMC (P \< 0.01).

![**Effect of exogenous LTD~4~or PMA challenge on isoproterenol-induced cAMP accumulation in HASMC**. *A-B*. Effects of leukotriene D~4~(LTD~4~, 10^-6^M) challenge and pretreatment with the CysLT~1~R antagonist montelukast (MK, 10^-6^M) on cAMP accumulation induced by multiple (*A*) and single (*B*, 10^-5^M) isoproterenol concentrations in HASMC. *C*. Effect of phorbol-12-myristate-13-acetate (PMA, 5 × l0^-7^M) challenge and pretreatment with the PKC inhibitor GF109203X (10^-6^M) on cAMP accumulation induced by 10^-5^M isoproterenol in HASMC. The results are presented as mean ± S.E.M. of at least three experiments performed in triplicate. \*\*P \< 0.01 (one-way ANOVA).](1465-9921-7-103-1){#F1}

After challenge with PMA (Fig. [1C](#F1){ref-type="fig"}), the maximum isoproterenol-induced cAMP accumulation was significantly (P \< 0.01) reduced to 52% ± 12 SEM of the maximal stimulation, suggesting that PKC plays a pivotal role in the regulation of β~2~-AR in HASMC. In GF109203X-treated and PMA-challenged HASMC, isoproterenol-induced cAMP accumulation was not significantly different from unchallenged HASMC and significantly greater than in untreated PMA-challenged HASMC (P \< 0.01).

More importantly, in GF109203X-treated and LTD~4~-challenged HASMC (Fig. [2](#F2){ref-type="fig"}) the maximal isoproterenol-induced cAMP accumulation was 3417 pmoles/mg prot (CV 5%), significantly (P \< 0.01) greater than 2464 pmoles/mg prot (CV 7%) in untreated LTD~4~-challenged HASMC and insignificantly different from 3632 pmol/mg prot (CV 5%) in unchallenged HASMC, confirming a critical role for PKC in the LTD~4~-induced β~2~-AR desensitization.

![**Effect of exogenous LTD~4~challenge and pretreatment with GFX109203X on isoproterenol-induced cAMP accumulation in HASMC**. Effects of LTD~4~(10^-6^M) challenge and pretreatment with GF109203X (10^-6^M) on cAMP accumulation induced by multiple (*A*) and single (*B*, 10^-5^M) isoproterenol concentrations in HASMC. The results are presented as mean ± S.E.M. of at least three experiments performed in triplicate. \*\*P \< 0.01 (one-way ANOVA).](1465-9921-7-103-2){#F2}

Pre-treatment with H89 did not alter the effect of LTD~4~challenge on isoproterenol-induced maximal cAMP accumulation (Fig. [3A](#F3){ref-type="fig"}), suggesting that LTD~4~-induced β~2~-AR desensitization does not involve PKA activation. Moreover, LTD~4~challenge did not affect the forskolin-induced maximal cAMP accumulation (Fig. [3B](#F3){ref-type="fig"}), suggesting that the adenylyl cyclase was not directly affected by LTD~4~.

![**Effect of exogenous LTD~4~challenge on isoproterenol- or forskolin-induced cAMP accumulation in HASMC**. *A*. Effects of LTD~4~(10^-6^M) challenge and pretreatment with the PKA inhibitor H89 (10^-6^M) on cAMP accumulation induced by single (10^-5^M) isoproterenol concentration in HASMC. *B*. Effects of LTD~4~(10^-6^M) challenge on cAMP accumulation induced by single (10^-4^M) forskolin concentration in HASMC. The results are presented as mean ± S.E.M. of at least two experiments performed in triplicate. \*\*P \< 0.01, \*P \< 0.05 (oneway ANOVA).](1465-9921-7-103-3){#F3}

Relaxant responses to salbutamol in human bronchial rings
---------------------------------------------------------

The mean weight of the 24 bronchial rings was 91 ± 5 mg. The mean resting force and the mean normalized-response to carbachol were 0.83 ± 0.05 g and 14 ± 2 gr/gr of tissue, without significant differences between sensitized, challenged, and treated rings Table [1](#T1){ref-type="table"}.

###### 

Physical and mechanical characteristics of the human bronchial rings used for different experiments.

  condition     n   muscle weight, g   resting force   CCh response, g/g of tissue
  ------------- --- ------------------ --------------- -----------------------------
  sensitized    5   72 ± 4             0.72 ± 0.04     12 ± 3
  challenged    6   77 ± 4             0.73 ± 0.11     12 ± 3
  MLK 10^-7^M   5   102 ± 14           0.91 ± 0.05     19 ± 5
  MLK 10^-6^M   5   109 ± 9            0.84 ± 0.15     14 ± 3
  GFX 10^-7^M   2   116; 99            0.96; 1.23      31; 10
  GFX 10^-6^M   1   96                 1.05            8

Data are mean ± s.e.m. or individual values.

Salbutamol relaxed bronchial rings significantly (P \< 0.01) in a concentration-dependent manner (Fig. [4](#F4){ref-type="fig"}). The salbutamol concentration-response curve of challenged rings was significantly (P \< 0.01) shifted to the right of the dose response curve of sensitized unchallenged rings, with significant differences (P \< 0.01) at salbutamol concentrations from 10^-6^M to 10^-5^M. Pre-treatment with either 10^-6^M or 10^-7^M montelukast displaced significantly (P \< 0.01) to the left of the concentration-response curves of challenged rings, with significant differences (P \< 0.05) at salbutamol concentrations from 10^-6^M to 10^-5^M.

![**Effect of the pretreatment with montelukast on salbutamol-induced relaxation in challenged human bronchial rings**. Relaxant responses to salbutamol in carbachol-contracted human bronchial rings. Values of 100 and 0 on y-axis represent maximal force in response to 10^-6^M carbachol and minimal force at 10^-4^M salbutamol, respectively. ▲, sensitized control rings (n = 5); ■, challenged-untreated rings (n = 6); ○, montelukast 10^-7^M-treated rings (n = 5); □, montelukast 10^-6^M-treated rings (n = 5). The results are presented as mean ± S.E.M. \*P \< 0.05 (two-way repeated-measure ANOVA followed by Bonferroni post-hoc test) ■ *vs*. ▲, ○, and □.](1465-9921-7-103-4){#F4}

The mean values for IC~50~of challenged rings was -5.49 ± 0.12 Log M significantly (P \< 0.05) higher than -6.07 ± 0.15 Log M of sensitized untreated rings (Fig. [5](#F5){ref-type="fig"}). The IC~50~values of challenged rings treated with 10^-6^M and 10^-7^M montelukast were -6.05 ± 0.03 and 5.96 ± 0.19, respectively, which were not significantly different from those of sensitized untreated rings. The IC~50~values of challenged rings treated with montelukast were lower than those of challenged rings (P \< 0.05 for 10^-6^M and P = 0.07 for 10^-7^M).

![**Salbutamol concentrations inhibiting 50% of active force in carbachol-contracted human bronchial rings**. Effects of montelukast on salbutamol concentrations inhibiting 50% of carbachol-induced contraction (IC~50~). \* P \< 0.05 challenged *vs*. sensitized and montelukast 10^-6^M, \# P = 0.07 challenged *vs*. montelukast 10^-7^M (one-way ANOVA followed by Bonferroni post-hoc test). Each symbol represent rings from the same subject.](1465-9921-7-103-5){#F5}

In challenged rings treated with either 10^-7^M or 10^-6^M GF109203X, the concentration-response curves to salbutamol were significantly (P \< 0.01) shifted to the left of the concentration-response curve of challenged rings (Fig. [6](#F6){ref-type="fig"}).

![**Effect of the pretreatment with the PKC inhibitor GF109203X on salbutamol-induced relaxation in challenged human bronchial rings**. Relaxant responses to salbutamol in five carbachol-contracted human bronchial rings. Values of 100 and 0 on y-axis represent maximal force in response to 10^-6^M carbachol and minimal force at 10^-4^M salbutamol, respectively. ■, challenged-untreated rings; ○, rings pre-treated with 10^-7^M GF109203X; ▲, ring pre-treated with 10^-6^M GF109203X.](1465-9921-7-103-6){#F6}

Discussion
==========

The major findings of the present study can be summarized as follows: 1) In HASMC, exogenous LTD~4~caused a reduction of isoproterenol-induced cAMP accumulation similar to that caused by direct activation of PKC, 2) this effect of LTD~4~was prevented not only by the CysLT~1~R antagonist montelukast, but also by direct inhibition of PKC, and 3) both montelukast and direct PKC inhibition prevented the reduction of response to salbutamol caused by allergen challenge of passively sensitized human bronchi.

Comments on methodology
-----------------------

We first constructed concentration response curves of isoproterenol-induced cAMP accumulation in HASMC utilizing a non-cumulative protocol. A maximum effect was clearly observed at isoproterenol concentration of 10^-5^M, and this was therefore used for subsequent single-concentration experiments. Isoproterenol was used in cAMP accumulation experiments because, as a full β-AR agonist, is more suited for the desensitization studies. The β~2~-AR selective partial agonist salbutamol was used for bronchial rings studies because it is the reference drug generally used for clinical studies. However, in two separate experiments we found that the effect of salbutamol on cAMP accumulation was much weaker than that of isoproterenol, while the relative reduction caused by LTD~4~challenge was similar to that observed using isoproterenol, being even slightly more pronounced (Fig. [7](#F7){ref-type="fig"}). Therefore, we are confident that the results of our HASMC and bronchial rings studies are comparable.

![**Effect of exogenous LTD~4~challenge on salbutamol-induced cAMP accumulation in HASMC**. Effect of LTD~4~(10^-6^M) challenge on cAMP accumulation induced by 10^-4^M salbutamol in HASMC. Note the weaker effect of salbutamol compare to isoproterenol (10^-5^M) and the similarity with the effects of LTD~4~in Fig.s 1-3. The results are presented as mean ± s.e.m. of two experiments performed in triplicate. \*P \< 0.01 (one-way ANOVA).](1465-9921-7-103-7){#F7}

Furthermore, the fact that after LTD~4~challenge in HASMC only the maximal cAMP accumulation was reduced, whereas only the IC~50~of salbutamol-induced relaxation was reduced might be explained by the fact that the relaxing effect of a β2 agonist is a far more downstream response than a second messenger (i.e. cAMP) production, and certainly involve the activation of other components downstream of the receptor, while the β2-AR may perform functions other than adenylyl cyclase activation \[[@B28]\], yet equally involved in bronchial relaxation.

As in our previous studies \[[@B23],[@B26],[@B29]-[@B31]\], human bronchial rings were passively sensitized by using a pool of sera containing high levels of specific IgEs but low levels of total IgEs. With this method of passive sensitization and allergen challenge, followed by repeated washouts, the force generation capacity of airway smooth muscle was not altered \[[@B23]\], which makes us confident that the reference force of 1 g and the level of pre-contraction induced by carbachol 10^-6^M were similar in all experimental conditions. Furthermore, the relaxant responses to either theophylline \[[@B26]\] or forskolin \[[@B30]\] remained unaltered in previous studies using the same methodology. Therefore, the use of sensitized unchallenged rings as a control seems justified and any difference in response to salbutamol can be attributed to changes in the β~2~-AR pathway.

For relaxation studies, bronchial rings were pre-contracted with the non-selective muscarinic agonist carbachol, thus activating both M~3~and M~2~receptors on smooth muscle cell membrane. M~2~receptors are coupled to G~i~-protein, which inhibits adenylyl cyclase. Thus, had sensitization or allergen challenge changed G~i~-protein expression or activity, the response to a β~2~-agonist would have been affected. In this model, however, both expression and activity of G~i~-protein were similar in sensitized and challenged rings \[[@B29]\].

In bronchial tissue studies, the effects of allergen challenge were presumably due to mediator release from resident inflammatory cells \[[@B23]\]. Thus, it cannot be excluded that the protective effects of GFX and montelukast against β~2~-AR dysfunction were in part due to inhibition of mediator release. However, the observation that GFX and montelukast also protected against β~2~-AR dysfunction in HASMC does suggest that airway smooth muscle PKC was directly involved

Comments on results
-------------------

The response to β~2~-AR has been found to be reduced in airways from subjects with fatal asthma \[[@B32]\]. A reduced β~2~-AR responsiveness in asthma may be the result of activation of the β~2~-AR by specific agonists (homologous desensitization) or activation of other receptors by the inflammatory mediators, which are present in the asthmatic airways (heterologous desensitization) \[[@B33]\]. β~2~-AR desensitization induced by agents that increase cAMP levels, such as bradykinin \[[@B34]\] and some cytokines \[[@B35]\] acting through the elevation of prostaglandin E~2~\[[@B36]\], is probably regulated by PKA \[[@B6],[@B33]\]. On the contrary, muscarinic agonists \[[@B37]\], phorbol esters, and other inflammatory mediators may attenuate responses to β-agonists through the activation of PKC \[[@B38]\], as also recently suggested in bovine tracheal smooth muscle preparations \[[@B39],[@B40]\]. However, it appears that these mechanisms of desensitization are cell-type specific \[[@B41]\] and may depend on kinase expression levels \[[@B42]\].

Among the inflammatory mediators involved in asthma, cysteinyl-LTs seem to play a key role in the bronchoconstrictor response to allergen \[[@B15]-[@B17]\] through activation of CysLT~1~R. Though preferentially coupled to G~q/11~-protein, constitutively expressed CysLT~1~also activates pertussis toxin (PTX)-sensitive and -insensitive G-proteins \[[@B43],[@B44]\]. In HASMC, we have previously found that CysLT~1~stimulation activates PKC \[[@B25]\] and mitogen-activated protein kinases ERK1/2 through mechanisms that involve a PTX-sensitive G-protein \[[@B19]\]. Thus, it is possible that cysteinyl-LTs may contribute to β~2~-AR desensitization not only by a PKC-dependent mechanism, but also by modulating the adenylyl cyclase-PKA pathway.

The results of the present study show that the cAMP accumulation in response to isoproterenol is reduced in HASMC treated with exogenous LTD~4~or the PKC activator PMA and the relaxant response to salbutamol is reduced in human bronchi challenged with the sensitizing allergen. The effects of LTD~4~in HASMC and allergen challenge in bronchial rings were prevented by the CysLT~1~R antagonist montelukast and the PKC specific inhibitor GF109203X. Altogether, these findings strongly suggest that in the models used in the present study β~2~-AR desensitization was the result of PKC activation by LTD~4~.

In HASMC, exogenous LTD~4~did not alter the cAMP accumulation induced by forskolin, thus excluding that the reduced response of β~2~-AR to isoproterenol was due to adenylyl cyclase dysfunction. The PKA inhibitor H89 also failed to prevent the LTD~4~-induced β~2~-AR desensitization in HASMC, thus ruling out the possibility of the involvement of this protein kinase. Indeed, H89 tended to enhance the response to isoproterenol both in LTD~4~-challenged and -unchallenged HASMC, suggesting the presence of the well known G~S~/G~i~switch phenomenon of β~2~-AR coupling due to PKA phosphorylation \[[@B45]\], which was not enhanced by LTD~4~. This finding suggests that the β~2~-AR function is independently modulated by PKA and PKC mechanisms and it is consistent with the observations by Penn et al. \[[@B6]\] who showed that inhibition of PKC did not alter β~2~-AR desensitization induced by PKA activation.

In human bronchi, allergen challenge may cause β~2~-AR desensitization through different mechanisms involving inflammatory mediators other than LTs, thus possibly involving PKA. However, in previous studies we found that the reduction of relaxant response to salbutamol in allergen-challenged rings was not prevented by inhibition of prostaglandins \[[@B23]\], IL-lβ, or TNFα \[[@B30]\], which are known to cause β~2~-AR dysfunction/desensitization through the activation of PKA \[[@B6],[@B33],[@B35],[@B36]\].

Conclusion
==========

In conclusion, taken together these data suggest that cysteinyl-LTs cause desensitization of β~2~-AR in both HASMC and isolated human bronchi through an acute mechanism involving PKC but not PKA, and that this desensitization might be prevented by the CysLT~1~R antagonist montelukast. If cysteinyl-LTs released from resident or circulating inflammatory cells or even from the smooth muscle cell itself are the major responsible for β~2~-AR desensitization in asthma, then the concurrent administration of CysLT~1~R antagonists may represent a useful tool to improve the response to β~2~-AR agonists in this disease. Clinical trials are necessary to assess the efficacy of the association between CysLT~1~R antagonists and β~2~-AR agonists in bronchial asthma.
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